Track the 셀트리온제약 share price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares are listed on KR KR, under the supervision of DART (FSS). Operating in the Health Care sector, 셀트리온제약 has recorded 97 public disclosures. Market capitalisation: €1,772.5bn. The latest transaction was disclosed on 10 April 2026 (Purchase). Among the most active insiders: 셀트리온. All data is accessible without an account.
97
Insider Decl.
n/a
Thresholds
€16m
36 ops.
Buy Volume
n/a
4 ops.
Sell Volume
30Σ signal
Buys €16mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 16,788 of 28,065 companies
46.0
score / 100
Value
39
Quality
53
FCF yld3.5%
Earn yld2.0%
EV/EBITDA26.6x
ROE8.9%
Gross mgn31%
Net mgn7.2%
Debt/EBITDA2.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Celltrion Healthcare is a South Korean pharmaceutical company focused on the development and manufacturing of biosimilar drugs. It is listed on the Korea Exchange, XKRX.